Patents by Inventor Richard Ashton

Richard Ashton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110110039
    Abstract: A housing includes a first chamber having an exhaust aperture to provide fluid communication with an outside environment, a wall disposed in the first chamber and containing an electrical component, wherein a thermal energy generated by the electrical component is transferred from the first chamber to the outside environment through the exhaust aperture, a second chamber formed adjacent the first chamber and including a control means for the electrical component, and a means for selectively providing access to the first chamber and the second chamber.
    Type: Application
    Filed: October 19, 2010
    Publication date: May 12, 2011
    Inventors: David Feltner, David E. Olin, Peter Gerhardinger, Richard Ashton
  • Patent number: 7892803
    Abstract: The invention relates generally to isolated leucoanthocyanidin reductase LAR polypeptides of the Reductase-Epimerase-Dehydrogenase (RED) protein family, and nucleic acid molecules encoding same and their use in regulating the biosynthesis and accumulation of proanthocyanidins in plants. The invention is further directed to isolated nucleic acid molecules of plants which encode leucoanthocyanidin reductases of the RED protein family. The isolated polypeptides and nucleic acid molecules of the present invention are useful for modifying the pasture quality of legumes, and, in particular, for producing bloat-safe forage crops. or crops having enhanced nutritional value, enhanced disease resistance or pest resistance, or enhanced malting qualities.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: February 22, 2011
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Gregory John Tanner, Anthony Richard Ashton, Sharon Abrahams, John McRae Watson, Philip John Larkin, Katarzyna Teresa Francki
  • Publication number: 20100261760
    Abstract: The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.
    Type: Application
    Filed: June 22, 2010
    Publication date: October 14, 2010
    Applicant: Asterand UK Limited
    Inventors: Alexander William Oxford, Richard John Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Patent number: 7803841
    Abstract: The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: September 28, 2010
    Assignee: Asterand UK Limited
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Publication number: 20100130556
    Abstract: A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L? is a single bond, —O— or —C(?O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.
    Type: Application
    Filed: August 9, 2006
    Publication date: May 27, 2010
    Applicant: ASTERAND UK LIMITED
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Shirley Ann Brunton, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd
  • Patent number: 7662839
    Abstract: A compound of formula (I): or a salt, or chemically protected form thereof, wherein: R5 is an optionally substituted phenyl; A is ?wherein Q is N; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl, and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl, and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl, and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl, and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: Where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm-alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally, when RP3 is —Cm-alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optional
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: February 16, 2010
    Assignee: Asterand UK Limited
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Publication number: 20090298899
    Abstract: The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.
    Type: Application
    Filed: December 30, 2008
    Publication date: December 3, 2009
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Patent number: 7582672
    Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: September 1, 2009
    Assignee: Oxagen Limited
    Inventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Eric R. Pettipher, Michael George Hunter, Mark Whittaker, Chris Palmer
  • Publication number: 20090023788
    Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 22, 2009
    Applicant: Oxagen Limited
    Inventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Eric Roy Pettipher, Michael George Hunter, Mark Whittaker, Chris Palmer
  • Publication number: 20090018139
    Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 15, 2009
    Applicant: Oxagen Limited
    Inventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
  • Publication number: 20090018338
    Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 15, 2009
    Applicant: Oxagen Limited
    Inventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
  • Publication number: 20090018138
    Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 15, 2009
    Applicant: Oxagen Limited
    Inventors: David Middlemiss, Mark Richard Ashton, Edward Andrew boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
  • Publication number: 20080311580
    Abstract: This inventions provides an isolated protein or polypeptide having activity in the synthesis of proanthocyanidin (PA) polymer from epicatechin or catechin in plants, and which is not naturally regulated by the TT2 or TT8 regulators, or a fragment comprising at least about 10 contiguous amino acids derived from said protein or polypeptide, particularly TDS1, TDS2, TDS3, TDS4, TDS5, or TDS6 protein, or fragment thereof. Also provided are nucleic acid encoding such proteins or polypeptides; plant cells and plants containing and expressing such nucleic acids; antibodies that bind to such proteins or polypeptides; and related methods.
    Type: Application
    Filed: January 28, 2008
    Publication date: December 18, 2008
    Inventors: Sharon Abrahams, Anthony Richard Ashton, Gregory John Tanner, Philip John Larkin
  • Publication number: 20080194574
    Abstract: The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke and especially for the treatment of herpesviral induced infections, including opportunistic infections as well as infections and diseases caused by human cytomegalovirus (HCMV).
    Type: Application
    Filed: December 16, 2004
    Publication date: August 14, 2008
    Applicant: AXXIMA PHARMACEUTICALS AG
    Inventors: Jan Eike Eikhoff, Mark Richard Ashton, Stephen Martin Courtney, Christopher John Yarnold, Maurizio Varrone, Pui Leng Loke, Thomas Herget, Wilfried Schwab, Doris Hafenbradl
  • Publication number: 20080119526
    Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3
    Type: Application
    Filed: December 5, 2007
    Publication date: May 22, 2008
    Applicant: PHARMAGENE LABORATORIES LIMITED
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Patent number: 7326732
    Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and t
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: February 5, 2008
    Assignee: Pharmagene Laboratories Limited
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Patent number: 7244599
    Abstract: The invention relates generally to isolated leucoanthocyanidin reductase LAR polypeptides of the Reductase-Epimerase-Dehydrogenase (RED) protein family, and nucleic acid molecules encoding same and their use in regulating the biosynthesis and accumulation of proanthocyanidins in plants. The invention is further directed to isolated nucleic acid molecules of plants, which encode leucoanthocyanidin reductases of the RED protein family. The isolated polypeptides and nucleic acid molecules of the present invention are useful for modifying the pasture quality of legumes, and, in particular, for producing bloat-safe forage crops, or crops having enhanced nutritional value, enhanced disease resistance or pest resistance, or enhanced malting qualities.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: July 17, 2007
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Meat and Livestock Australia Limited
    Inventors: Gregory John Tanner, Anthony Richard Ashton, Sharon Abrahams, John McRae Watson, Philip John Larkin, Katarzyna Teresa Francki
  • Patent number: 6898833
    Abstract: The present invention relates to an apparatus for removing articles from a continuous manufacturing line without interrupting the line comprising a pair of conveyor portions arranged in substantially parallel alignment, each having means for transporting an article along the manufacturing line and being mounted on a frame, the frame being reversibly transportable between a first and second position in a direction substantially orthogonal to the direction of travel of an article on the manufacturing line, said first and second positions corresponding with a conveyor portion being in alignment with the continuous manufacturing line.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: May 31, 2005
    Assignee: Ashton Industrial Sales Limited
    Inventor: Stephen Richard Ashton
  • Publication number: 20040191787
    Abstract: The invention relates generally to isolated leucoanthocyanidin reductase LAR polypeptides of the Reductase-Epimerase-Dehydrogenase (RED) protein family, and nucleic acid molecules encoding same and their use in regulating the biosynthesis and accumulation of proanthocyanidins in plants. The invention is further directed to isolated nucleic acid molecules of plants which encode leucoanthocyanidin reductases of the RED protein family. The isolated polypeptides and nucleic acid molecules of the present invention are useful for modifying the pasture quality of legumes, and, in particular, for producing bloat-safe forage crops, or crops having enhanced nutritional value, enhanced disease resistance or pest resistance, or enhanced malting qualities.
    Type: Application
    Filed: March 15, 2004
    Publication date: September 30, 2004
    Inventors: Gregory John Tanner, Anthony Richard Ashton, Sharon Abrahams, John McRae Watson, Philip John Larkin, Katarzyna Teresa Francki
  • Publication number: 20030146066
    Abstract: The present invention relates to an apparatus for removing articles from a continuous manufacturing line without interrupting the line comprising a pair of conveyor portions arranged in substantially parallel alignment, each having means for transporting an article along the manufacturing line and being mounted on a frame, the frame being reversibly transportable between a first and second position in a direction substantially orthogonal to the direction of travel of an article on the manufacturing line, said first and second positions corresponding with a conveyor portion being in alignment with the continuous manufacturing line.
    Type: Application
    Filed: December 13, 2002
    Publication date: August 7, 2003
    Applicant: Ashton Industrial Sales Limited
    Inventor: Stephen Richard Ashton